Download Image
    
Share
  
Post
Edaravone for COVID-19
1 study with 38 patients
Hospital Icon Control
Hospital Icon Edaravone Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Edaravone studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -50% Mortality -50% RCTs -50% Late -50% Favorsedaravone Favorscontrol
Jun 20
2022
 Moslemi et al., Inflammopharmacology, doi:10.1007/s10787-022-01001-2 Evaluating the effect of Edaravone on clinical outcome of patients with severe COVID-19 admitted to ICU: a randomized clinical trial
75% lower ventilation (p=0.06) and 10% longer ICU admission (p=0.92). RCT 38 severe COVID-19 ICU patients showing lower need for endotracheal intubation, but no significant difference in mortality with edaravone.